Sporotrichosis treatment: Overview and update

Current Fungal Infection Reports

Volumn 5, Issue 1, 2011, Pages 42-48

  Bustamante, Beatriz ^a,b   Campos, Pablo E ^c,d  

^a HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d Investigaciones Médicas en Salud INMENSA ^*  (Peru)

Author keywords

Fungal infection; Itraconazole; Potassium iodide; Sporothrix schenckii; Sporotrichosis; Terbinafine

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MELANIN; POSACONAZOLE; POTASSIUM IODIDE; RAVUCONAZOLE; TERBINAFINE; VIRULENCE FACTOR;

AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; BILIRUBIN BLOOD LEVEL; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FLU LIKE SYNDROME; FUNGAL VIRULENCE; HUMAN; HYPERTHERMIC THERAPY; IN VITRO STUDY; LUNG SPOROTRICHOSIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OSTEOARTICULAR SPOROTRICHOSIS; PATHOGENESIS; REVIEW; SIDE EFFECT; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; SUBCUTANEOUS MYCOSIS; SUBCUTANEOUS SPOROTRICHOSIS; TREATMENT DURATION; URTICARIA; VOMITING;

EID: 79952195264     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0041-7     Document Type: Review

References (45)

1. Bustamante B, Campos PE. Endemic sporotrichosis. Curr Opin Infect Dis 2001; 14:145-149. (Pubitemid 32231100)
2. Barros MB, Schubach Ade O, do Valle AC, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis 2004; 38:529-535.
3. Pappas PG, Tellez I, Nolazco D, et al. Sporotrichosis in Peru: Description of a hyperendemic area. Clin Infect Dis 2000; 30:65-70. (Pubitemid 30067064)
4. Marimon R, Gené J, Cano J, et al. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol 2006; 44:3251-3256. (Pubitemid 44413760)
5. Marimon R, Cano J, Gené J, et al. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol 2007; 45:3198-3206. (Pubitemid 47585640)
6. Marimon R, Gené J, Cano J, Guarro J. Sporothrix luriei: a rare fungus from clinical origin. Med Mycol 2008; 46:621-625.
7. Arrillaga-Moncrieff I, Capilla J, Mayayo E, et al. Different virulence levels of the species of Sporothrix in a murine model. Clin Microbiol Infect 2009; 15:651-655. The authors demonstrate for first time that species of the S. schenckii complex have different degrees of virulence.
8. Trilles L, Fernández-Torres B, Dos Santos Lazéra M, et al. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother 2005; 49:3952-3954
9. Kohler LM, Soares BM, de Assis Santos D, et al. In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms. Can J Microbiol 2006; 52:843-847.
10. Ghosh A, Chakrabarti A, Hemashettar BM, Maiti PK. In vitro susceptibility pattern of Sporothrix schenckii strains isolated from three centers in India. Indian J Med Res 2001; 113:214-220.
11. Kohler LM, Monteiro PC, Hahn RC, Hamdan JS. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J Clin Microbiol 2004; 42:4319-4320.
12. McGinnis MR, Nordoff N, Li RK, et al. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin. B Med Mycol 2001; 39:369-371. (Pubitemid 32791487)
13. Romero-Martinez R, Wheeler M, Guerrero-Plata A, et al. Biosynthesis and functions of melanin in Sporothrix schenckii. Infect Immun 2000; 68:3696-3703. (Pubitemid 30340476)
14. Morris-Jones R, Youngchim S, Gomez BL, et al. Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection. Infect Immun 2003; 71:4026-4033. (Pubitemid 36753729)
15. Almeida-Paes R, Frases S, Fialho Monteiro PC, et al. Growth conditions influence melanization of Brazilian clinical Sporothrix schenckii isolates. Microbes Infect 2009; 11:554-562.
16. Madrid IM, Xavier MO, Mattei AS, et al. Role of melanin in the pathogenesis of cutaneous sporotrichosis. Microbes Infect 2010; 12:162-165. This study showed that melanized S. schenckii isolates had greater tissue invasive capacity than albino isolates, supporting the probable role of melanin in Sporothrix virulence.
17. Nosanchuk JD, Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 2006; 50:3519-3528. (Pubitemid 44684860)
18. Rubio G, Sánchez G, Porras L, Alvarado Z. Sporotrichosis: prevalence, clinical and epidemiological features in a reference center in Colombia. Rev Iberoam Micol. 2010 30; 27:75-79.
19. da Rosa AC, Scroferneker ML, Vettorato R. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451-459.
20. Bustamante B, Lama JR, Mosquera C, Soto L. Sporotrichosis in human immunodeficiency virus infected Peruvian patients: two case reports and literature review. Infect Dis Clin Pract 2009; 17:78-83. This comprehensive review describes clinical manifestations and outcome of the primary treatment of sporotrichosis in HIV-infected patients.
21. Galhardo MC, Silva MT, Lima MA, et al. Sporothrix schenckii meningitis in AIDS during immune reconstitution syndrome. J Neurol Neurosurg Psychiatry 2010; 81: 696-699.
22. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007; 45:1255-1265.
23. Antunes Tde A, Nobre Mde O, Faria RO, et al. Experimental cutaneous sporotrichosis: in vivo evaluation of itraconazole and terbinafine. Rev Soc Bras Med Trop 2009; 42:706-710.
24. Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitis and cutaneous sporotrichosis. Arch Dermatol 1986; 122:413-417. (Pubitemid 16132910)
25. Conti-Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole.Mycoses 1992; 35:153-156.
26. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95, 279-285. (Pubitemid 23270285)
27. Noguchi H, Hiruma M, Kawada A. Case report. Sporotrichosis successfully treated with itraconazole in Japan. Mycoses 1999; 42, 571-576.
28. Gupta A, Lambert J, Revuz J, Shear N. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol 2001; 11:6-10. (Pubitemid 32150371)
29. Ameen M. Managing chromoblastomycosis. Trop Doct 2010;40:65-67.
30. Bonifaz A, Fierro L, Saúl A, Ponce RM. Cutaneous sporotrichosis. Intermittent treatment (pulses) with itraconazole. Eur J Dermatol 2008; 18:61-64. (Pubitemid 351158174)
31. Song Y, Zhong SX, Yao L, et al. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol 2010 Jul 6 (Epub ahead of print). The promising results of this pilot study suggest a new itraconazole regimen useful for the treatment of subcutaneous sporotrichosis.
32. Wada R. Studies of mode of action of potassium iodide upon sporotrichosis. Mycopathologia 1968; 34:97-107.
33. Hiruma M, Kagawa S. Ultrastructure of Sporothrix schenckii treated with iodine-potassium iodide solution. Mycopathologia 1987; 97:121-127. (Pubitemid 17033004)
34. Bustamante B, Campos PE. Sporotrichosis: a forgotten disease in the drug research agenda. Expert Rev Anti Infect Ther 2004; 2:85-94. (Pubitemid 38735750)
35. Mahajan VK, Sharma NL, Sharma RC, et al. Cutaneous sporotrichosis in Himachal Pradesh, India. Mycoses 2005; 48:25-31.
36. Morishita N, Yamazaki K, Ninomiya J, et al. A case of lymphocutaneous sporotrichosis. Nippon Ishinkin Gakkai Zasshi 2001; 42:149-154. (Pubitemid 32738212)
37. Cabezas C, Bustamante B, Holgado W, Begué R. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr Infect Dis J 1996; 15:352-354. (Pubitemid 26119278)
38. Kan VL, Bennett JE. Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob Agents Chemother 1988; 32:1619-1623. (Pubitemid 18267603)
39. Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg/day) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47:62-68. (Pubitemid 38375600)
40. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126 (Suppl 39), 51-55.
41. Francesconi G, Valle A, Passos S, et al. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol 2009; 23:1273-1276.
42. Marimon R, Serena C, Gené J, et al. In vitro antifungal susceptibilities of five species of Sporothrix. Antimicrob Agents Chemother 2008; 52:732-734. This paper shows that the different species of the S. schenckii complex have different responses to 12 antifungal drugs.
43. Diaz M, Negroni R, Montero-Gei F, et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis 1992; 14(Suppl 1):S68-76.
44. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950-2856.
45. Hiruma M, Kawada A, Noguchi H, et al. Hyperthermic treatment of sporotrichosis: experimental use of infrared and far infrared rays. Mycoses 1992; 35: 293-299. (Pubitemid 23093739)